Sandra Calvin Sells 3,348 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 3,348 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $67,361.76. Following the completion of the transaction, the chief accounting officer now owns 63,654 shares of the company’s stock, valued at $1,280,718.48. This trade represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $21.21 on Thursday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The firm has a 50-day simple moving average of $18.74 and a 200 day simple moving average of $15.51. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $21.86. The company has a market cap of $1.66 billion, a PE ratio of -4.66 and a beta of 0.72.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Piper Sandler lifted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. HC Wainwright lifted their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $9.00 to $27.00 in a report on Monday, October 21st. Barclays raised their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, Wedbush upped their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently made changes to their positions in TVTX. US Bancorp DE lifted its holdings in shares of Travere Therapeutics by 323.4% in the 4th quarter. US Bancorp DE now owns 31,795 shares of the company’s stock worth $554,000 after purchasing an additional 24,286 shares during the last quarter. Bank of New York Mellon Corp increased its position in Travere Therapeutics by 3.6% in the fourth quarter. Bank of New York Mellon Corp now owns 216,863 shares of the company’s stock worth $3,778,000 after buying an additional 7,513 shares during the period. Impax Asset Management Group plc bought a new stake in Travere Therapeutics in the fourth quarter valued at $5,226,000. Ieq Capital LLC bought a new stake in Travere Therapeutics in the fourth quarter valued at $361,000. Finally, Rhumbline Advisers boosted its holdings in shares of Travere Therapeutics by 2.2% during the fourth quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock valued at $2,112,000 after acquiring an additional 2,640 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.